Thursday, 18 Oct 2018

You are here

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

The CALM study was multicenter, open-label, randomised, controlled phase 3 study, in adults with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6 and a Crohn's Disease Activity Index (CDAI) of 150–450 in patients who were DMARD and biologic naive.

Patients were randomized 1:1 ratio to either tight control or clinical management groups. After 8 weeks of prednisone induction therapy, treatment was escalated in a stepwise manner, from adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathioprine.

The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomisation. 

Dose escalation was different between groups. The Tight Control group used mulitiple definitions of failure (fecal calprotectin ≥250 μg/g, C-reactive protein ≥5mg/L, CDAI ≥150, or prednisone use), while the clinical management group only used changes in the CDAI or prednisone use.

A total of  244 patients were enrolled w/ a mean disease duration < 1 year. Significantly more Tight Control patients achieved the primary endpoint at week 48 (46%) compared to those with usual care (30%) (p=0·010).

There were no unexpected adverse events which were balanced between groups; and there were no treatment-related deaths. Dropouts were equal between groups (24-26%), mostly due to adverse events.

CALM is the first study to show that timely escalation, using an advanced tight control strategy, can lead to clinical and endoscopic outcomes than symptom-driven decisions alone. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

TNF Inhibitors Don't Increase Cancer Risk in Children

While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population.